Webinar

Mastering the complexity of CGT process development - how to meet challenges on the path to commercialization

On-demand

Bringing cell and gene therapy (CGT) products to market is not without its challenges. In this roundtable discussion, experts will discuss how to overcome these hurdles in cell and gene process development and manufacturing and how this can help biotech companies on their way to commercial readiness. 

Learn from experts discussing critical factors and solutions related to scalability, process optimization, automation and compliance, and quality assurance.

Webinar learning objectives

  • Better understanding of the ecosystem/valley of uncertainties when transitioning from early drug discovery phases towards commercial CMC (chemistry, manufacturing, and controls) preparedness.
  • Learn how CMC platform technologies can help to keep flexibility throughout the process discovery phase while ultimately delivering robustness towards clinical & commercial manufacturing.
  • Learn how to ensure scalability and consistency beyond manufacturing & QC when transitioning from small-scale to commercial-scale production
  • Understand key supply chain parameter and how to manage a commercial ramp-up successfully.

Boris Engels, PhD

Senior Scientific Director for Gene-Engineered T Cell Therapies, Miltenyi Biotec B.V. & Co. KG

With expertise in cancer immunology, he leads teams advancing CAR- and TCR-redirected T cells for life-threatening diseases.
Previously at Novartis, he developed cell therapies, and at the University of Chicago, he explored TCR interactions. He holds a Ph.D. in biology from the Max-Delbrück Centre for Molecular Medicine, Berlin.

Daniel Jakobs, PhD

Senior Manager Cell Factory, Miltenyi Biotec B.V. & Co. KG

Daniel Jakobs PhD, is a senior director for manufacturing and supply chain at the Bergisch Gladbach CliniMACS Cell Factory® of Miltenyi Biotec. He is responsible for the scale up of the clinical manufacturing and the set-up of commercial manufacturing of CAR-T products.
Prior to moving to the cell and gene therapy manufacturing he held positions as head of pharma packaging at Grünenthal Aachen, Germany and head of manufacturing at Bausch + Lomb Berlin, Germany. Daniel studied pharmacy at Bonn University, Germany where he also received a PhD in pharmacy.

Dr. Hermann Bohnenkamp

VP – Business Development APAC, Miltenyi Biotec B.V. & Co. KG

Dr. Hermann Bohnenkamp, VP – Business Development APAC at Miltenyi Biotec B.V. & Co. KG, brings over 15 years of experience spearheading clinical marketing, country management, and business development. With a strong background in CAR T cell product development and global commercialization, Hermann has driven success through strategic alliances.
Prior roles include project manager at MediGene Immunotherapies, contributing to early clinical asset development, and positions focusing on dendritic cell vaccines and T cell manufacturing.
Hermann, a trained chemist with a doctorate in chemistry and technical chemistry, is dedicated to advancing healthcare through innovative solutions.

Silvio Weber, PhD

Scientific Director Industrial Workflow Development Cellular Therapy, Miltenyi Biotec B.V. & Co. KG

With over 15 years of R&D experience in cell biology, including immunology and regenerative medicine, he leads the delivery of automated cell and gene therapy procedures using the CliniMACS Prodigy® Instrument Platform.
Silvio coordinates the development of customized processes for T-cell immunotherapy and stem cell engineering, among other innovative approaches.
He holds a diploma in biochemistry from the University of Bielefeld and a Ph.D. in biochemistry from the University of Kiel.